HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A correction has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Condie, C. K. Articles by Canann, D. M. Search for Related Content PubMed PubMed Citation Articles by Condie, C. K. Articles by Canann, D. M.

CHAD K. CONDIE, PHARM.D., is Clinical Pharmacist, University of Utah Healthcare (UUH), Salt Lake City. LINDA S. TYLER, PHARM.D., FASHP, is Director, Drug Information Service, UUH, and Professor (Clinical), Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City. BRIAN BARKER, B.S.PHARM., is Clinical Pharmacist, and DAVID M. CANANN, PHARM.D ., is Clinical Pharmacist, UUH.

Address correspondence to Dr. Condie at the Department of Pharmacy Services, Room A-050, University of Utah Hospital, 50 North Medical Drive, Salt Lake City, UT 84132.

Purpose. The physical compatibility of i.v. caspofungin with other commonly used i.v. medications was tested. Methods. Two methods were used to combine caspofungin and the secondary drugs. For drugs administered by i.v. push, caspofungin was delivered through a poly-vinyl chloride (PVC) i.v. solution set with secondary drugs injected into the Y-site of the i.v. extension set. For drugs given by i.v. infusion (over 10 minutes), secondary drugs were infused into the Y-site of the i.v. solution set through microbore PVC tubing. The two drugs shared 39 in of tubing. Attached to each end of the i.v. extension set were 0.8-µm filter disks. All drug combinations were tested three times; after each infusion, the filters were bubble-point tested. Drug combinations were considered physically compatible if no visible precipitate was seen and no color change was noted by the unaided eye during the infusion, or if the number of particles found on the filter under a microscope did not exceed the number stated in United States Pharmacopeia guidelines for particulate levels of large-volume parenteral fluids. Results. A total of 8 of the 31 drugs tested (acyclovir, ceftriaxone, cefazolin, clindamycin, furosemide, heparin, pantoprazole, and piperacillin–tazobactam) were found to be physically incompatible with caspofungin. Conclusion. Caspofungin acetate was physically compatible during Y-site injection with 23 of 31 medications tested. Index terms: Antifungals; Caspofungin acetate; Incompatibilities; Injections; Poly-vinyl chloride; Stability; Tubing

 

This article has been cited by other articles:

				D. Canann, L. S. Tyler, B. Barker, and C. Condie Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am. J. Health Syst. Pharm., April 15, 2009; 66(8): 727 - 729. [Abstract] [Full Text] [PDF]

				D. W. Newton Membrane-filter bubble-point test Am. J. Health Syst. Pharm., December 1, 2008; 65(23): 2210 - 2212. [Full Text] [PDF]